Prospects of a new anti-staphylococcal drug batumin revealed by molecular docking and analysis of the complete genome sequence of the batumin producer Pseudomonas batumici UCM B-321 to mupirocin, batumin could inhibit a broader range of aminoacyl tRNA synthetases and the acquired resistance to mupirocin might not endow S. aureus strains with resistance against batumin.
Introduction
Staphylococcus aureus is a major human pathogen that is capable of causing a wide range of human diseases resulting in significant morbidity and mortality. Methicillin resistant S. aureus (MRSA) became especially problematic in hospitals. Several new prospective polyketide antibiotics were isolated from different species of gamma-Proteobacteria, which can selectively suppress growth of S. aureus including multi-drug resistant strains in concentration of 0.05 μg/ml [1, 2, 3] . Among these antibiotics, only mupirocin is widely used in medicine.
However, multiple cases of mupirocin resistance have been reported [4] . It calls for a search for new active antistaphylococcal antibiotics, which may replace or supplement mupirocin. One such antibiotic, which no resistance has been reported for, is batumin/kalimantacin. Three different producers of this antibiotics have been reported:
Pseudomonas batumici UCM B-321 [2] , P.fluorescens BCCM_ID9359 [5] and Alcaligenes sp. YL-02632S [6] .
Both batumin and mupirocin are encoded by large hybrid PKS-NRPS operons sharing some level of sequence similarity [3, 5] . A common chemical property of mupirocin and batumin is 9-hydroxy-nonanoic acid residue present in their structures. Antimicrobial activity of both these antibiotics against several Gram-positive and Gramnegative bacteria is summarized in Table 1 [3, 7, 8] . To work out a possibility to replace or supplement mupirocin with other antibiotics to overcome mupirocin resistance, mechanisms of antibacterial activity of these antibiotics should be compared. Different target proteins were reported for batumin and mupirocin despite the obvious similarities in their structures and anti-staphylococcal specificity.
The mechanism of activity of batumin was proposed by Mattheus et al. [9] . Investigation of possible contribution of all genes of the batumin operon toward synthesis of this antibiotic revealed that the protein BatG took no part in the synthesis but showed a sequence similarity to trans-enoyl-CoA reductase FabI involved in fatty acid biosynthesis. This enzyme was known as a target for many antibiotics. It was supposed that BatG might act as an antidote against batumin to protect the producer against toxicity of this antibiotic. Expression of BatG in S. aureus in a shuttle vector conferred the resistance to batumin and to triclosan, which was another FabI inhibitor [9] . In this work it was shown also that BatG could complement mutations of FabI in E. coli. From these observations it was concluded that FabI was the target protein for batumin. However, no molecular docking analysis has been performed on possibility for batumin to bind to FabI molecules.
Mupirocin has been used since 1985 to prevent MRSA infection in hospitals [7] . It was shown in further publications that the mupirocin had bound specifically to an active site in Rossmann fold domain in bacterial isoleucine-tRNA-synthase (IleRS) [10] . In this work, a crystal structure of the S. aureus IleRS complex with tRNA Ile and mupirocin was demonstrated. In a later work by Nakama et al. [11] , another crystal structure of mupirocin bound to Thermus thermophilus IleRS was published. It was supposed that inhibition of IleRS by mupirocin disrupted protein synthesis in bacteria [12] . Later it was found out that impact of mupirocin was more profound and involved induction of stringent response in bacteria [13] . Soon after the introduction of mupirocin to medical practice, cases of mupirocin resistant S. aureus have been reported. Two types of mupirocin resistance were observed: low level resistance resulted from point mutations in the native gene ileRS and high-level resistance mediated by a plasmid born mupA gene possibly of a eukaryotic origin that encoded an alternative IleRS with no affinity to mupirocin [4] . The genetic analysis of mupirocin resistance cases undoubtedly demonstrated that IleRS was the target protein for mupirocin.
Objective of this work was to model binding of batumin and mupirocin to different possible target proteins with an aim to summarize peculiarities of mechanisms of anti-bacterial activity of these antibiotics, which may explain observed differences in MIC (Table 1 ) and reported inability of S. aureus to develop resistance to batumin [14] .
Methods

Bacterial growth conditions and DNA isolation
Pseudomonas batumici UCM B-321 was obtained from the Ukrainian Collection of Microorganisms (UCM) at Danylo Zabolotny Institute of Microbiology and Virology, National Academy of Science of Ukraine, Kiev, Ukraine. The stock culture was preserved by lyophilization at 4 C. The culture was routinely grown on peptonemeat-infusion agar at 26 C. Genomic DNA from overnight bacterial culture was extracted using GeneJet TM Genomic DNA Purification Kit (Fermentas). The quality of DNA samples were controlled by electrophoresis in 0.8% agarose gel.
Complete genome sequencing
In total 32,533,165 paired-end reads of the total length of 6,362,883,728 bp were generated by Illumina Hi-Seq 
Genome annotation and analysis
An automatic annotation of contigs by the RAST server identified 5,834 possible protein coding sequences, 2 fragmented ribosomal RNA operons and 54 tRNA genes. The complete genome sequence of P. batumici UCM B-321 and supplementary data were deposited at NCBI under accession numbers JXDG00000000, BioProject PRJNA270768 and BioSample SAMN03273282.
Identification of horizontally acquired genomic islands was performed by using SeqWord Genomic Island Sniffer 1.1 at http://www.bi.up.ac.za/SeqWord/sniffer/index.html [15] . known precisely from the corresponding crystal structures [10, 11] , mupirocin served in this study as a positive control for in silico docking.
Molecular docking
Both the ligands bound to IleRS active site by multiple hydrogen and hydrophobic bonds. The maximal total binding energy of the calculated receptor-ligand structures is shown in Table 2 . The predicted affinity of mupirocin was a bit higher than that predicted for batumin, especially in IleRS Common target amino acids were Gly56, Glu550, Asp553, Trp558, Leu583 and Ile584. The 9-hydroxy-nonanoic acid residue in the mupirocin structure did not participate in binding to IleRS. This aliphatic residue may be of It may be concluded that both batumin and mupirocin can bind with a similar energy to IleRS active site, but none of them can bind to FabI. This finding contradicted to the report by Mattheus et al. [9] that the expression of BatG, a batumin tolerant analog of FabI from the batumin operon, could confer resistance to this antibiotic. However, according to Reiss et al. [13] , inhibition of IleRS may influence FabI activity. This observation reconciles this contradiction. In the latter work by Reiss et al. [13] , a global metabolome analysis was performed to study the profound action of mupirocin on S. aureus. It was found out that accumulation of uncharged isoleucyl-tRNA molecules resulted from IleRS inhibition had triggered the stringent response by activation of (p)ppGpp alarmone.
The alarmone induces a cascade of events of up and down regulation of gene expression. Particularly, a significant down-regulation of FabH was reported. FabH is an enzyme that feeds the FAS II cycle [16] . Suppression of expression of this gene can be caused by suspension of the fatty acid biosynthesis cycle. It was not the first report of fatty acid biosynthesis inhibition during the stringent response. Heath et al. [17] 
demonstrated in experiments on
Escherichia coli that (p)ppGpp inhibited the phospholipid synthesis through regulation at the glycerol-P acyltransferase step followed by accumulation of long-chain acyl-ACP. It was observed that the phospholipid synthesis had shifted from initiation of fatty acid biosynthesis to utilization of the end products by acyltransferases.
This observation was confirmed in a recent publication by My et at. [18] , who reported that the fatty acid biosynthesis and particularly fabHDG operon in E. coli was inhibited by (p)ppGpp through FadR and FabR transcriptional regulators. This physiologically process is not critical for many bacteria, as they can compensate the lack of synthesized fatty acids by uptake of exogenous molecules. However, suppression of fatty acid synthesis 8 becomes lethal for S. aureus because of a peculiarity of the regulation of fatty acid metabolism in this bacterium suppressing at the same time both the synthesis and incorporation of exogenous fatty acids [19] . In the latter paper it was explained why FabI inhibitors were much more toxic to S. aureus than to other micro-organisms.
Several conclusions may be derived from this study, which should be experimentally tested in the future work: i) batumin does not inhibit FabI but acts similar to mupirocin by targeting aminoacyl tRNA synthetases; ii) batumin and mupirocin inhibit S. aureus through impairing the fatty acid biosynthesis pathway in a similar way as the FabI inhibitors did, but through triggering an abnormal stringent response; iii) batG encodes a FabI-like trans-enoylCoA reductase that could confer resistant to endogenous FabI inhibitors expressed during the stringent response.
Analysis of the complete genome of P. batumici UCM B-321
Operon of biosynthesis of batumin/kalimantacin in P. fluorescens BCCM_ID9359 was known from previous publications [5, 9] . Exactly the same operon of 74,151 bp was found in P. batumici UCM B-321. The difference was only in one nucleotide deletion in a spacer region that also could be a sequencing error. The gene map of the batumin operon of UCM B-321 is shown in Fig 3. The average GC-content of the genome of UCM B-321 was 61.78%. In the locus covering the batumin operon, the GC-content was below 50% (see Fig 3) . An acquisition of this locus by horizontal gene transfer was confirmed by search for genomic islands (GIs) using the program SWGIS. The atlas of concatenated contigs of UCM B-321 with locations of predicted GIs is shown in Fig 4. It was known that the resistance to mupirocin was associated with the presence of alternative isoleucine-tRNAsynthases showing no affinity to mupirocin [4] . We searched for genes encoding aminoacyl tRNA synthetases in the genome of UCM B-321. A complete set of aminoacyl-tRNA synthetases charging all 20 amino acids was found. There was no redundancy of isoleucyl-tRNA synthetases but 3 paralogs of leucyl-tRNA synthetases were higher affinity to leucyl-tRNA synthetase rather than to isoleucyl-tRNA synthetase. Inhibition of leucyl-tRNA synthetase leads to the same consequences ending up with triggering of abnormal stringent response by accumulation of uncharged tRNA molecules. Indeed, isoleucyl-and leucyl-tRNA synthases share significant sequence similarity in domains composing batumin binding sites. Alternative versions of LeuRS and FabI might be required to confer resistance of the strain-producer to batumin. This specificity in the mechanisms of antibiotic activity of batumin and mupirocin may explain the observed differences in the profile of susceptible bacterial testcultures shown in Table 1 .
Conclusion
Public health care experiences a serious problem with emerging and quick distribution of antibiotic resistance among pathogens. Development of new antibiotics is costly and time consuming process. Very often resistance to newly developed antibiotics has emerged soon after its introduction into practice. Expenses for antibiotic development and introduction are getting so immense with the profit being so unpredictable that many pharmaceutical companies refused investing into design of new antibiotics. Possible solution lies in optimization of the therapy by combining antibiotics, which do not share the resistance patterns. By using molecular docking modeling and genome comparison, it was shown that batumin in many aspects is an analog of mupirocin that has been used successfully for decades in medicine against MRSA infection. In the same time, the current research 
